Disease · EFO_0007248
egg allergy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. egg allergy. Diseases, record EFO_0007248. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0007248
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs4
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| OMALIZUMAB | CHEMBL1201589 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| INFLUENZA A VIRUS, SPLIT VIRION | CHEMBL6068363 | Vaccine component | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| INFLUENZA VIRUS VACCINE | CHEMBL2109042 | Vaccine component | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| IGHE | Immunoglobulin heavy constant epsilon | 1 | Ig epsilon chain C region inhibitor | Phase 3 | https://conductscience.org/library/genes/3497 |
Source Drugs and targets
Trials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03881696 | Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants | Phase 3 | 458 | 2024-06-04 | Peanut Allergy, Multi-food Allergy | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03181009 | Multi OIT to Test Immune Markers After Minimum Maintenance Dose | Phase 2 | 60 | 2019-09-20 | Food Allergy | OMALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01264601 | Safe Administration of Flu Vaccine to Egg Allergic Children | Not applicable | 31 | 2017-10-26 | Egg Allergy | SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT06103656 | E-B-FAHF-2, Multi OIT and Xolair for Food Allergy | Phase 2 | 33 | Food Allergy | OMALIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Omalizumab vs Placebo for Omalizumab: deaths from any cause | 0 of 120 | 0 of 60 | 180 | NCT03881696 | Trial comparisons |
| Omalizumab vs Placebo for Omalizumab: serious adverse events | 4 of 120 | 1 of 60 | 180 | NCT03881696 | Trial comparisons |
| Group A (300 mg Maintenance Dose) vs Group B (1200 Maintenance Dose): deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT03181009 | Trial comparisons |
| Group A (300 mg Maintenance Dose) vs Group B (1200 Maintenance Dose): serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT03181009 | Trial comparisons |
| Single Dose vs Graded Challenge: serious adverse events | 0 of 17 | 0 of 14 | 31 | NCT01264601 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0007248
GET https://conductscience.org/api/diseases/v1/EFO_0007248/drugs